AstraZeneca appoints chief executive

Pascal Soriot joins the firm on 1 October

Pascal Soriot has been appointed as chief executive of AstraZeneca. He will take on his new responsibilities and join the AstraZeneca board as an executive director on 1 October.

Simon Lowth will remain as AstraZeneca’s interim chief executive until Soriot joins. Lowth will then resume the position of chief financial officer and will continue to serve on the AstraZeneca board.

Soriot joins AstraZeneca from Roche where, since 2010, he has been chief operating officer of the pharmaceuticals division.

Prior to that he was chief executive of Genentech, where he was credited with leading the successful merger between the San Francisco-based biologics business and Roche.

Soriot also worked for Sanofi-Aventis from 1986 to 2005 in senior management roles in the US, Asia and Europe.

You may also like

Manufacturing

AstraZeneca invests $3.5bn into its US pharmaceutical research and manufacturing capabilities

The company will expand its biologics manufacturing, as well as its speciality manufacturing and cell therapy production capacity, while also extending its pharmaceutical research and development capabilities through this investment
Drug Delivery

AstraZeneca and Amgen's Tezspire meets primary endpoints in Phase III trial

The Phase III WAYPOINT trial demonstrated Tezspire's ability to reduce nasal polyps and congestion compared to placebo when administered subcutaneously
Ingredients

Therapeutic: brensocatib for bronchiectasis

The chronic lung disease bronchiectasis is a serious condition in which the bronchi become permanently dilated because of a cycle of infection, inflammation and damage to the lung tissue
Regulatory

AstraZeneca's Wainzua recommended for EU approval to treat amyloidosis

The neuropathy drug was developed in tandem with Ionis, and has been shown to reduce neuropathy and increase quality of life in the Phase III NEURO-TTransform trial
Research & Development

AstraZeneca's asthma-targeting Airsupra meets primary endpoint in Phase III trial

The inhaled therapeutic has proven effective in reducing the risk of severe asthma attacks in patients with intermittent or persistent asthma
Regulatory

AstraZeneca's Tagrisso obtains FDA approval for use in stage III NSCLC

Tagrisso reduced the risk of disease progression or death by 84% compared to placebo in the Phase III LAURA trial
Design & Build

AstraZeneca opens a 'people hub' at its Macclesfield site

The energy-efficient building will offer AZ employees a collaborative space
Subscribe now